Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Black Diamond Therapeutics (BDTX) Cash from Operations (2019 - 2025)

Black Diamond Therapeutics' Cash from Operations history spans 5 years, with the latest figure at 6787000.0 for Q4 2025.

  • For Q4 2025, Cash from Operations rose 54.92% year-over-year to 6787000.0; the TTM value through Dec 2025 reached 29614000.0, up 147.53%, while the annual FY2025 figure was 29614000.0, 147.53% up from the prior year.
  • Cash from Operations reached 6787000.0 in Q4 2025 per BDTX's latest filing, up from 7850000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 53410000.0 in Q1 2025 to a low of 24455000.0 in Q1 2021.
  • Average Cash from Operations over 3 years is 6349333.33, with a median of 11323000.0 recorded in 2024.
  • Peak YoY movement for Cash from Operations: tumbled 116.05% in 2021, then surged 351.95% in 2025.
  • A 3-year view of Cash from Operations shows it stood at 24455000.0 in 2021, then surged by 38.44% to 15055000.0 in 2024, then surged by 54.92% to 6787000.0 in 2025.
  • Per Business Quant, the three most recent readings for BDTX's Cash from Operations are 6787000.0 (Q4 2025), 7850000.0 (Q3 2025), and 9159000.0 (Q2 2025).